SARS-CoV-2 viral load is linked to remdesivir efficacy in
severe Covid-19 admitted to intensive care

J 2024

SARS-CoV-2 viral load is linked to remdesivir efficacy in severe Covid-19 admitted to intensive care

BALIK, M., P. WALDAUF, I. JURISINOVA, E. SVOBODOVA, M. DIBLICKOVA et. al.

Základní údaje

Originální název

SARS-CoV-2 viral load is linked to remdesivir efficacy in severe Covid-19 admitted to intensive care

Autoři

BALIK, M. (203 Česká republika), P. WALDAUF (203 Česká republika), I. JURISINOVA (203 Česká republika), E. SVOBODOVA (203 Česká republika), M. DIBLICKOVA (203 Česká republika), T. TENCER (203 Česká republika), J. ZAVORA (203 Česká republika), G. SMELA (203 Česká republika), L. KUPIDLOVSKA (203 Česká republika), V. ADAMKOVA (203 Česká republika), M. FRIDRICHOVA (203 Česká republika), K. JERABKOVA (203 Česká republika), J. MIKES (203 Česká republika), F. DUSKA (203 Česká republika) a Ladislav DUŠEK (203 Česká republika, domácí)

Vydání

Nature Scientific Reports, Berlin, NATURE RESEARCH, 2024, 2045-2322

Další údaje

Jazyk

angličtina

Typ výsledku

Článek v odborném periodiku

Obor

30221 Critical care medicine and Emergency medicine

Stát vydavatele

Německo

Utajení

není předmětem státního či obchodního tajemství

Odkazy

URL

Impakt faktor

Impact factor: 4.600 v roce 2022

Organizační jednotka

Lékařská fakulta

DOI

http://dx.doi.org/10.1038/s41598-024-71588-9

UT WoS

001308223300068

Klíčová slova anglicky

SARS-CoV-2; Viral load; Remdesivir; Real-time PCR; Antigen testing; Intensive care

Štítky

14119612, rivok

Příznaky

Mezinárodní význam, Recenzováno

Změněno: 23. 9. 2024 12:08, Mgr. Tereza Miškechová

Anotace

V originále

Remdesivir therapy has been declared as efficient in the early stages of Covid-19. Of the 339 patients (males 55.8%, age 71(59;77) years) with a detectable viral load, 140 were treated with remdesivir (of those 103 in the ICU and 57 immunosuppressed) and retrospectively compared with 199 patients (of those 82 in the ICU and 28 immunosuppressed) who were denied therapy due to advanced Covid-19. The viral load was estimated by detecting nucleocapsid antigen in serum (n = 155, median 217(28;1524)pg/ml), antigen in sputum (n = 18, COI 18(4.6;32)), nasopharyngeal antigen (n = 44, COI 17(8;35)) and the real-time PCR (n = 122, Ct 21(18;27)). After adjustment for confounders, patients on remdesivir had better 12-month survival (HR 0.66 (0.44;0.98), p = 0.039), particularly when admitted to the ICU (HR 0.49 (0.29;0.81), p = 0.006). For the immunocompromised patients, the difference did not reach statistical significance (HR 0.55 (0.18;1.69), p = 0.3). The other most significant confounders were age, ICU admission, mechanical ventilation, leukocyte/lymphocyte ratio, admission creatinine and immunosuppression. The impact of monoclonal antibodies or previous vaccinations was not significant. Despite frequent immune suppression including haemato-oncology diseases, lymphopenia, and higher inflammatory markers in the remdesivir group, the results support remdesivir administration with respect to widely available estimates of viral load in patients with high illness severity.

Citovat

BALIK, M., P. WALDAUF, I. JURISINOVA, E. SVOBODOVA, M. DIBLICKOVA, T. TENCER, J. ZAVORA, G. SMELA, L. KUPIDLOVSKA, V. ADAMKOVA, M. FRIDRICHOVA, K. JERABKOVA, J. MIKES, F. DUSKA a Ladislav DUŠEK. SARS-CoV-2 viral load is linked to remdesivir efficacy in severe Covid-19 admitted to intensive care. Nature Scientific Reports. Berlin: NATURE RESEARCH, 2024, roč. 14, č. 1, s. 1-13. ISSN 2045-2322. Dostupné z: https://dx.doi.org/10.1038/s41598-024-71588-9.

@article{2436017,
   author = {Balik, M. and Waldauf, P. and Jurisinova, I. and Svobodova, E. and Diblickova, M. and Tencer, T. and Zavora, J. and Smela, G. and Kupidlovska, L. and Adamkova, V. and Fridrichova, M. and Jerabkova, K. and Mikes, J. and Duska, F. and Dušek, Ladislav},
   article_location = {Berlin},
   article_number = {1},
   doi = {http://dx.doi.org/10.1038/s41598-024-71588-9},
   keywords = {SARS-CoV-2; Viral load; Remdesivir; Real-time PCR; Antigen testing; Intensive care},
   language = {eng},
   issn = {2045-2322},
   journal = {Nature Scientific Reports},
   title = {SARS-CoV-2 viral load is linked to remdesivir efficacy in severe Covid-19 admitted to intensive care},
   url = {https://www.nature.com/articles/s41598-024-71588-9},
   volume = {14},
   year = {2024}
}

TY  - JOUR
ID  - 2436017
AU  - Balik, M. - Waldauf, P. - Jurisinova, I. - Svobodova, E. - Diblickova, M. - Tencer, T. - Zavora, J. - Smela, G. - Kupidlovska, L. - Adamkova, V. - Fridrichova, M. - Jerabkova, K. - Mikes, J. - Duska, F. - Dušek, Ladislav
PY  - 2024
TI  - SARS-CoV-2 viral load is linked to remdesivir efficacy in severe Covid-19 admitted to intensive care
JF  - Nature Scientific Reports
VL  - 14
IS  - 1
SP  - 1-13
EP  - 1-13
PB  - NATURE RESEARCH
SN  - 20452322
KW  - SARS-CoV-2
KW  - Viral load
KW  - Remdesivir
KW  - Real-time PCR
KW  - Antigen testing
KW  - Intensive care
UR  - https://www.nature.com/articles/s41598-024-71588-9
N2  - Remdesivir therapy has been declared as efficient in the early stages of Covid-19. Of the 339 patients (males 55.8%, age 71(59;77) years) with a detectable viral load, 140 were treated with remdesivir (of those 103 in the ICU and 57 immunosuppressed) and retrospectively compared with 199 patients (of those 82 in the ICU and 28 immunosuppressed) who were denied therapy due to advanced Covid-19. The viral load was estimated by detecting nucleocapsid antigen in serum (n = 155, median 217(28;1524)pg/ml), antigen in sputum (n = 18, COI 18(4.6;32)), nasopharyngeal antigen (n = 44, COI 17(8;35)) and the real-time PCR (n = 122, Ct 21(18;27)). After adjustment for confounders, patients on remdesivir had better 12-month survival (HR 0.66 (0.44;0.98), p = 0.039), particularly when admitted to the ICU (HR 0.49 (0.29;0.81), p = 0.006). For the immunocompromised patients, the difference did not reach statistical significance (HR 0.55 (0.18;1.69), p = 0.3). The other most significant confounders were age, ICU admission, mechanical ventilation, leukocyte/lymphocyte ratio, admission creatinine and immunosuppression. The impact of monoclonal antibodies or previous vaccinations was not significant. Despite frequent immune suppression including haemato-oncology diseases, lymphopenia, and higher inflammatory markers in the remdesivir group, the results support remdesivir administration with respect to widely available estimates of viral load in patients with high illness severity.
ER  -

BALIK, M., P. WALDAUF, I. JURISINOVA, E. SVOBODOVA, M. DIBLICKOVA, T. TENCER, J. ZAVORA, G. SMELA, L. KUPIDLOVSKA, V. ADAMKOVA, M. FRIDRICHOVA, K. JERABKOVA, J. MIKES, F. DUSKA a Ladislav DUŠEK. SARS-CoV-2 viral load is linked to remdesivir efficacy in severe Covid-19 admitted to intensive care. \textit{Nature Scientific Reports}. Berlin: NATURE RESEARCH, 2024, roč.~14, č.~1, s.~1-13. ISSN~2045-2322. Dostupné z: https://dx.doi.org/10.1038/s41598-024-71588-9.

Podrobný výpis o publikaci